Lily Lee, MD
Plastic and Reconstructive Surgery · Pasadena, CANPI 1730311226
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $692 of the $1,142 with a category attached, or 60.6%. 6 manufacturers reported payments, led by Galderma Laboratories, L.p. at 54.5% of the total. Reporting peaked in 2019 at $575 and has fallen 87.9% since, to $70 in 2025. That places this record below the midpoint for plastic and reconstructive surgery clinicians in CA, where the typical reported total is $1,879.
Across 39 payments — averaging $29.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$622
- AbbVie$432
- Revance Therapeutics, Inc.$43
- Motiva USA, LLC$20
- Apyx Medical Corporation$13
- Merz North America, Inc.$13
What the payments were for
- Speaking & faculty fees$45039%
- Food & beverage$69261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 9 | $622 |
| AbbVie(2 entities) | 24 | $432 |
| Revance Therapeutics, Inc. | 2 | $43 |
| Motiva USA, LLC | 1 | $20 |
| Apyx Medical Corporation | 2 | $13 |
| Merz North America, Inc. | 1 | $13 |
How this compares
$1,142 in reported general payments places this provider in the 40th percentile of 349 plastic and reconstructive surgery providers in California.
See all plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 153 | $1,293 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Pasadena
- Mark SuskiThousand Oaks$294K
- Corey MaasSan Francisco$286K
- Arian MowlaviLaguna Beach$250K
- Charles LeeSan Francisco$200K
- David SieberSan Francisco$195K
- David KulberLos Angeles$194K
- Matthew NykielUpland$181K
- Subhas GuptaLoma Linda$178K
- Jeffrey HammoudehLos Angeles$159K
- Geoffrey GurtnerPalo Alto$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.